Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.78
NAS:EGLT's Cash to Debt is ranked lower than
74% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:EGLT: 1.78 )
Ranked among companies with meaningful Cash to Debt only.
NAS:EGLT' s Cash to Debt Range Over the Past 10 Years
Min: 0.91  Med: N/A Max: No Debt
Current: 1.78
Equity to Asset 0.38
NAS:EGLT's Equity to Asset is ranked lower than
80% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:EGLT: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
NAS:EGLT' s Equity to Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.51 Max: 0.85
Current: 0.38
0.24
0.85
F-Score: 3
Z-Score: -1.18
M-Score: 4.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -223.28
NAS:EGLT's Operating margin (%) is ranked lower than
61% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:EGLT: -223.28 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:EGLT' s Operating margin (%) Range Over the Past 10 Years
Min: -1934.17  Med: -692.37 Max: -223.28
Current: -223.28
-1934.17
-223.28
Net-margin (%) -244.27
NAS:EGLT's Net-margin (%) is ranked lower than
62% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:EGLT: -244.27 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:EGLT' s Net-margin (%) Range Over the Past 10 Years
Min: -2250.73  Med: -740.47 Max: -244.27
Current: -244.27
-2250.73
-244.27
ROE (%) -97.42
NAS:EGLT's ROE (%) is ranked lower than
81% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:EGLT: -97.42 )
Ranked among companies with meaningful ROE (%) only.
NAS:EGLT' s ROE (%) Range Over the Past 10 Years
Min: -444.79  Med: -265.8 Max: -86.8
Current: -97.42
-444.79
-86.8
ROA (%) -42.27
NAS:EGLT's ROA (%) is ranked lower than
63% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:EGLT: -42.27 )
Ranked among companies with meaningful ROA (%) only.
NAS:EGLT' s ROA (%) Range Over the Past 10 Years
Min: -307.77  Med: -140.37 Max: -42.27
Current: -42.27
-307.77
-42.27
ROC (Joel Greenblatt) (%) -762.75
NAS:EGLT's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:EGLT: -762.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:EGLT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1093.04  Med: -854.74 Max: -672.52
Current: -762.75
-1093.04
-672.52
» NAS:EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

EGLT Guru Trades in Q2 2015

Jim Simons 36,400 sh (New)
» More
Q3 2015

EGLT Guru Trades in Q3 2015

Jim Simons 31,800 sh (-12.64%)
» More
Q4 2015

EGLT Guru Trades in Q4 2015

Jim Simons 47,300 sh (+48.74%)
» More
Q1 2016

EGLT Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ARGS, NAS:CARA, NAS:CYAD, OTCPK:MXDHF, NAS:STML, NAS:QURE, AMEX:MDGN, NAS:VTL, NAS:FLKS, NAS:CASC, NAS:VCYT, NAS:CBMG, AMEX:PIP, NAS:RDHL, NAS:ABEO, AMEX:AST, OTCPK:SPHRY, AMEX:PFNX, NAS:NVIV, NAS:RGLS » details
Egalet Corp is a specialty pharmaceutical company. The Company is engaged in developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications.

Ratios

vs
industry
vs
history
P/B 3.93
EGLT's P/B is ranked lower than
51% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. EGLT: 3.93 )
Ranked among companies with meaningful P/B only.
EGLT' s P/B Range Over the Past 10 Years
Min: 1.41  Med: 3.03 Max: 9.79
Current: 3.93
1.41
9.79
P/S 6.02
EGLT's P/S is ranked higher than
68% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. EGLT: 6.02 )
Ranked among companies with meaningful P/S only.
EGLT' s P/S Range Over the Past 10 Years
Min: 3.5  Med: 60.25 Max: 670
Current: 6.02
3.5
670
Current Ratio 3.68
EGLT's Current Ratio is ranked lower than
56% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. EGLT: 3.68 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.92 Max: 29.19
Current: 3.68
0.86
29.19
Quick Ratio 3.62
EGLT's Quick Ratio is ranked lower than
55% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. EGLT: 3.62 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.86 Max: 29.19
Current: 3.62
0.86
29.19
Days Inventory 207.14
EGLT's Days Inventory is ranked lower than
71% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. EGLT: 207.14 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s Days Inventory Range Over the Past 10 Years
Min: 102.49  Med: 102.49 Max: 207.14
Current: 207.14
102.49
207.14
Days Sales Outstanding 11.00
EGLT's Days Sales Outstanding is ranked higher than
87% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. EGLT: 11.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.72  Med: 81.92 Max: 321.28
Current: 11
4.72
321.28
Days Payable 481.21
EGLT's Days Payable is ranked higher than
95% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. EGLT: 481.21 )
Ranked among companies with meaningful Days Payable only.
EGLT' s Days Payable Range Over the Past 10 Years
Min: 481.21  Med: 827.64 Max: 827.64
Current: 481.21
481.21
827.64

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.62
EGLT's Price/Net Cash is ranked lower than
63% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. EGLT: 9.62 )
Ranked among companies with meaningful Price/Net Cash only.
EGLT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.15  Med: 4.18 Max: 26.24
Current: 9.62
2.15
26.24
Price/Net Current Asset Value 7.81
EGLT's Price/Net Current Asset Value is ranked lower than
61% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. EGLT: 7.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EGLT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.09  Med: 4.07 Max: 21.92
Current: 7.81
2.09
21.92
Price/Tangible Book 4.81
EGLT's Price/Tangible Book is ranked higher than
50% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. EGLT: 4.81 )
Ranked among companies with meaningful Price/Tangible Book only.
EGLT' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.9  Med: 3.48 Max: 14.68
Current: 4.81
1.9
14.68
Price/Median PS Value 0.10
EGLT's Price/Median PS Value is ranked higher than
97% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. EGLT: 0.10 )
Ranked among companies with meaningful Price/Median PS Value only.
EGLT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 1.05 Max: 8.58
Current: 0.1
0.06
8.58
Earnings Yield (Greenblatt) (%) -39.76
EGLT's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. EGLT: -39.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EGLT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -318.41  Med: 0 Max: 0
Current: -39.76
-318.41
0

More Statistics

Revenue (TTM) (Mil) $27.20
EPS (TTM) $ -2.67
Short Percentage of Float26.20%
52-Week Range $4.34 - 14.67
Shares Outstanding (Mil)25.12

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 37 57 88
EPS ($) -3.47 -3.10 -2.40 -1.35
EPS w/o NRI ($) -3.47 -3.10 -2.40 -1.35
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:EGLT

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
Editorial Discussing Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids... Sep 27 2016
Egalet Announces Publications in Pain Medicine from ARYMO™ ER Oral and Intranasal Human Abuse... Sep 22 2016
ETF’s with exposure to Egalet Corp. : September 19, 2016 Sep 19 2016
Egalet Appoints Patrick Shea as Chief Commercial Officer Sep 19 2016
Egalet Appoints Patrick Shea as Chief Commercial Officer Sep 19 2016
Coverage initiated on Egalet by Gabelli & Co Sep 13 2016
Egalet Announces OXAYDO® Demonstrates Bioequivalence at 15 mg Dose Sep 12 2016
Egalet Announces OXAYDO® Demonstrates Bioequivalence at 15 mg Dose Sep 12 2016
Egalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability Sep 08 2016
Egalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability Sep 08 2016
EGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Sep 01 2016
Egalet Completes $40 Million Secured Debt Financing Aug 31 2016
EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 26 2016
Egalet Announces Scientific Presentations at PAINWeek 2016 Meeting Aug 25 2016
Egalet (EGLT) in Focus: Stock Moves 7.2% Higher in Session Aug 24 2016
ETF’s with exposure to Egalet Corp. : August 17, 2016 Aug 17 2016
EGALET CORP Financials Aug 16 2016
Egalet Corp. :EGLT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Egalet (EGLT) Catches Eye: Stock Adds 6.8% in Session Aug 08 2016
EGALET CORP Files SEC form 10-Q, Quarterly Report Aug 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)